期刊文献+

成人急性B淋巴细胞白血病患者基因突变谱及预后意义 被引量:7

Spectrum of somatic mutations and their prognostic significance in adult patients with B cell acute lymphoblastic leukemia
原文传递
导出
摘要 【摘要】目的探讨成人急性B淋巴细胞白血病(B—ALL)患者的基因突变谱,并分析其对患者预后的影响。方法收集113例2009年6月至2015年9月收治的成人B—ALL患者DNA标本,采用靶向特异的二代测序技术,针对血液恶性疾病相关的112种基因进行突变分析,通过多个数据库筛选出可能致病的基因突变,描述其发生频谱,并通过Kaplan—Meier、Cox回归模型分析突变基因对患者总生存(OS)和无复发生存(RFS)的影响。结果113例患者中103例(92.0%)发生至少一种基因突变,29例(25.6%)患者发生≥3种基因突变。所有患者中突变率较高的基因有SFl、FATl、MPL、PTPNll、NRAS等,Ph阳性B—ALL和Ph阴性B—ALL患者中基因突变特点不尽一致。进一步分析基因突变对患者预后的影响,发现在Ph阴性B—ALL中伴JAK—STAT信号通路相关基因突变的患者(如JAKl、JAK2突变)较该信号通路未受影响的患者预后差(OS:P值分别为0.011和0.001;RFS:P值分别为0.014和〈0.001),而伴PTPNll突变的B—ALL患者较不伴PTPN11突变的患者有较好的OS及RFS,但差异无统计学意义(P值均〉0.05);在Ph阳性B.ALL患者中,表观遗传学修饰相关的信号通路异常的患者预后较差(OS:P=0.038;RFS:P=0.047)。结论基因突变在成人B.ALL中存在普遍性,发生频谱因亚型而异,涉及多种信号通路,JAK家族相关基因突变常提示患者预后较差,突变基因之间的共存现象也预示着成人B—ALL患者的遗传复杂性和不稳定性。 Objective To investigate the spectrum of gene mutations in adult patients with B-acute lymphoblastic leukemia (B-ALL), and to analyze the influences of different gene mutations on prognosis. Methods DNA samples from 113 adult B-ALL patients who administered from June 2009 to September 2015 were collected. Target-specific next generation sequencing (NGS) approach was used to analyze the mutations of 112 genes (focused on the specific mutational hotspots) and all putative mutations were compared against multiple databases to calculate the frequency spectrum. The impact of gene mutation on the patients' overall survival (OS) and recurrence free survival (RFS) was analyzed by the putative mutations through Kaplan-Meier, and Cox regression methods. Results Of the 113 patients, 103 (92.0%) harbored at least one mutation and 29 (25.6%) harbored more than 3 genes mutation. The five most frequently mutated genes in B-ALL are SF1, FAT1, MPL, PTPNll and NRAS. Gene mutations are different between Ph+ B-ALL and Ph-B-ALL patients. Ph- B-ALL patients with JAK-STAT signal pathway related gene mutation, such as JAK1/JAK2 mutation showed a poor prognosis compared to the patients without mutation (OS: P = 0.011, 0.001 ; RFS: P = 0.014, 〈 0.001). Patients with PTPN11 mutation showed better survival than those without mutation, but the difference was not statistically significant (P value 〉 0.05). Besides, in Ph+ B-ALL patients whose epigenetic modifications related signaling pathway genes were affected, they had a worse prognosis (OS: P = 0.038; RFS: P = 0.047). Conclusion Gene mutations are common in adult ALL patients, a variety of signaling pathways are involved. The frequency and spectrum are varied in different types of B-ALL. JAK family gene mutation usually indicates poor prognosis. The co- occurrence of somatic mutations in adult B-ALL patients indicate the genetic complex and instability of adult B-ALL patients.
出处 《中华血液学杂志》 CAS CSCD 北大核心 2018年第2期98-104,共7页 Chinese Journal of Hematology
基金 国家科技支撑计划(2014BA109812) 天津市应用基础与前沿技术研究计划(15JCZD.JC36400) 天津市科技计划项目(15ZXLCSY00010)
关键词 白血病 B细胞 二代测序技术 DNA突变分析 预后 Leukemia, B- cell Target- specific next- generation sequencing DNA mutational analysis Prognosis
  • 相关文献

参考文献1

二级参考文献12

  • 1van Dongen JJ, Macintyre EA, Gabert JA, et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action : investigation of minimal residual disease in acute leukemia. Leukemia, 1999,13 : 1901-1928.
  • 2Chan KW. Acute lymphoblastic leukemia. Curr Probl Pediatr Adolesc Health Care, 2002, 32:4049.
  • 3Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia. N Engl J Med, 2004, 350:1535-1548.
  • 4Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med, 2006,354:166-178.
  • 5Pui CH, Sallan S, Relling MV, et al. International Childhood Acute Lymphoblastic Leukemia workshop: Sausalito, CA, 30 November-1 December 2000. Leukemia, 2001,15: 707-715.
  • 6Takeuchi J, Kyo T, Naito K, et al. Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL93 study. Leukemia, 2002, 16: 1259-1266.
  • 7Gokbuget N, Hoelzer D. Treatment of adult acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program, 2006: 133-141.
  • 8Rowe JM, Buck G, Burnett AK, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ ECOG E2993. Blood, 2005, 106:3760-3767.
  • 9Vitale A, Guarini A, Ariola C, et al. Adult T-cell acute lymphoblastic leukemia: biologic profile at presentation and correlation with response to induction treatment in patients enrolled in the GIMEMA LAL 0496protocol. Blood, 2006, 107: 473-479.
  • 10Kantarjian H, Thomas D, O' Brien S, et al. Long-term follow-up results of hyperfractionated cyclophosphamide vincristine, doxorubicin, and dexamethasone (Hyper-CVAD) , a dose-intensive regimen, in acute lymphoblastic leukemia. Cancer, 2004, 101: 2788-2801.

共引文献24

同被引文献39

引证文献7

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部